User login
Key clinical point: Adagrasib shows favorable clinical efficacy without any new safety signals in patients with previously treated KRASG12C-mutated nonsmall cell lung cancer (NSCLC).
Major finding: Among patients with measurable disease at baseline, 42.9% had a confirmed objective response. The median progression-free survival was 6.5 (95% CI 4.7-8.4) months. At a median follow-up of 15.6 months, the median overall survival was 12.6 (95% CI 9.2-19.2) months. The treatment-related adverse events of grade 1/2 and 3 occurred in 52.6% and 44.8% of patients, respectively.
Study details: This registrational phase 2 cohort study investigated adagrasib in 116 patients with KRASG12C-mutated NSCLC previously treated with platinum-based chemotherapy with or without anti-programmed death 1 or programmed death ligand 1 therapy.
Disclosures: The study was funded by Mirati Therapeutics. The authors reported ties with one or more pharmaceutical companies, including employment or stock options in Mirati Therapeutics.
Source: Jänne PA et al. Adagrasib in non–small-cell lung cancer harboring a KRASG12Cmutation. N Engl J Med. 2022 (Jun 3). Doi: 10.1056/NEJMoa2204619
Key clinical point: Adagrasib shows favorable clinical efficacy without any new safety signals in patients with previously treated KRASG12C-mutated nonsmall cell lung cancer (NSCLC).
Major finding: Among patients with measurable disease at baseline, 42.9% had a confirmed objective response. The median progression-free survival was 6.5 (95% CI 4.7-8.4) months. At a median follow-up of 15.6 months, the median overall survival was 12.6 (95% CI 9.2-19.2) months. The treatment-related adverse events of grade 1/2 and 3 occurred in 52.6% and 44.8% of patients, respectively.
Study details: This registrational phase 2 cohort study investigated adagrasib in 116 patients with KRASG12C-mutated NSCLC previously treated with platinum-based chemotherapy with or without anti-programmed death 1 or programmed death ligand 1 therapy.
Disclosures: The study was funded by Mirati Therapeutics. The authors reported ties with one or more pharmaceutical companies, including employment or stock options in Mirati Therapeutics.
Source: Jänne PA et al. Adagrasib in non–small-cell lung cancer harboring a KRASG12Cmutation. N Engl J Med. 2022 (Jun 3). Doi: 10.1056/NEJMoa2204619
Key clinical point: Adagrasib shows favorable clinical efficacy without any new safety signals in patients with previously treated KRASG12C-mutated nonsmall cell lung cancer (NSCLC).
Major finding: Among patients with measurable disease at baseline, 42.9% had a confirmed objective response. The median progression-free survival was 6.5 (95% CI 4.7-8.4) months. At a median follow-up of 15.6 months, the median overall survival was 12.6 (95% CI 9.2-19.2) months. The treatment-related adverse events of grade 1/2 and 3 occurred in 52.6% and 44.8% of patients, respectively.
Study details: This registrational phase 2 cohort study investigated adagrasib in 116 patients with KRASG12C-mutated NSCLC previously treated with platinum-based chemotherapy with or without anti-programmed death 1 or programmed death ligand 1 therapy.
Disclosures: The study was funded by Mirati Therapeutics. The authors reported ties with one or more pharmaceutical companies, including employment or stock options in Mirati Therapeutics.
Source: Jänne PA et al. Adagrasib in non–small-cell lung cancer harboring a KRASG12Cmutation. N Engl J Med. 2022 (Jun 3). Doi: 10.1056/NEJMoa2204619